Profiling patent compounds in lipid nanoparticle formulations of siRNA
Lipid nanoparticles (LNPs) have emerged as a prominent delivery system for nucleic acid drugs, attracting significant attention, especially through the successful development of several commercial products. As a key component in LNPs, cationic lipids have long served as a key technical barrier to bl...
Saved in:
Main Authors: | Yunfeng Han (Author), Mengyang Wang (Author), Yu Chen (Author), Defang Ouyang (Author), Ying Zheng (Author), Yuanjia Hu (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2024-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Advances in Lipid Nanoparticles for siRNA Delivery
by: Sam Chen, et al.
Published: (2013) -
Effect of the amount of cationic lipid used to complex siRNA on the cytotoxicity and proinflammatory activity of siRNA-solid lipid nanoparticles
by: Mahmoud S. Hanafy, et al.
Published: (2023) -
siRNA Functionalized Lipid Nanoparticles (LNPs) in Management of Diseases
by: Tutu Kalita, et al.
Published: (2022) -
Doxorubicin-conjugated siRNA lipid nanoparticles for combination cancer therapy
by: Kamila Butowska, et al.
Published: (2023) -
Antibody-siRNA conjugates (ARC): Emerging siRNA drug formulation
by: Weiran Cao, et al.
Published: (2022)